Epilepsia Open

Scope & Guideline

Championing high-quality research in neurology and epilepsy.

Introduction

Immerse yourself in the scholarly insights of Epilepsia Open with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherWILEY
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationEPILEPSIA OPEN / Epilepsia Open
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

Epilepsia Open is dedicated to advancing the understanding, diagnosis, and treatment of epilepsy through high-quality research. The journal encompasses a wide range of topics related to epilepsy, including clinical, translational, and basic science studies. It aims to bridge the gap between laboratory research and clinical practice, ensuring that findings contribute to improved patient outcomes.
  1. Clinical Research in Epilepsy:
    The journal publishes studies focusing on the clinical aspects of epilepsy, including treatment efficacy, safety profiles of anti-seizure medications, and surgical interventions. This includes observational studies, clinical trials, and systematic reviews that provide insights into patient management.
  2. Genetic and Molecular Studies:
    Research that investigates the genetic underpinnings of epilepsy, including the identification of pathogenic variants and their implications for treatment. This area emphasizes the integration of genetics into clinical practice, such as genetic testing and personalized medicine approaches.
  3. Neurophysiology and Neuroimaging:
    The journal features studies employing advanced neurophysiological techniques like EEG, SPECT, and MRI to better understand the mechanisms of epilepsy. This includes research on seizure prediction, biomarkers, and the impact of neuroimaging on surgical outcomes.
  4. Psychosocial Aspects of Epilepsy:
    Articles addressing the psychosocial impact of epilepsy on patients and their families, including stigma, mental health comorbidities, and quality of life assessments. This aspect highlights the importance of holistic care in epilepsy management.
  5. Innovative Therapies and Interventions:
    Research on novel therapeutic approaches, including digital health interventions, dietary therapies (like the ketogenic diet), and neuromodulation techniques such as vagus nerve stimulation. This includes both clinical efficacy studies and pilot trials.
The journal has demonstrated a dynamic evolution in its research focus, showcasing several emerging themes that reflect current trends in epilepsy research. These areas are gaining attention and are likely to shape future investigations.
  1. Digital Health and Telemedicine:
    With the rise of digital health technologies, there is an increasing focus on telemedicine and digital interventions for epilepsy management. Studies exploring the effectiveness of mobile apps and online platforms for patient engagement and self-management are becoming more prevalent.
  2. Precision Medicine and Genetic Testing:
    The integration of genetic testing into clinical practice for epilepsy is gaining momentum, with more studies focusing on personalized treatment approaches based on individual genetic profiles. This trend is significant as it aligns with the broader movement towards precision medicine.
  3. Long-term Outcomes and Quality of Life Assessments:
    There is a growing emphasis on long-term outcomes and quality of life in epilepsy patients. Research is increasingly looking at how treatment impacts not just seizure control but also overall well-being and daily functioning.
  4. Comorbidities in Epilepsy:
    Research exploring the relationship between epilepsy and various comorbid conditions, such as psychiatric disorders, cognitive impairment, and metabolic issues, is on the rise. This reflects a holistic approach to understanding the complexities of epilepsy.
  5. Novel Treatment Modalities:
    Emerging therapies, including cannabinoids, neuromodulation techniques, and dietary interventions, are gaining attention. Research is focusing on their efficacy and safety, indicating a shift towards exploring alternative treatment options beyond traditional medications.

Declining or Waning

While the journal covers a broad spectrum of epilepsy research, certain themes appear to be declining in prominence based on recent publications. These waning topics may reflect shifts in research focus or the emergence of new areas of interest.
  1. Historical Perspectives on Epilepsy:
    There has been a noticeable reduction in papers focusing on the historical context and evolution of epilepsy as a medical condition, indicating a shift towards more contemporary clinical and scientific studies.
  2. Pharmacokinetics of Older Antiepileptic Drugs:
    Research centered on the pharmacokinetics and safety profiles of older anti-seizure medications is less frequent, as newer therapies and their comparative effectiveness take precedence in recent studies.
  3. Epidemiological Studies in Low-Income Regions:
    While still relevant, the volume of epidemiological studies focusing on epilepsy in low-resource settings has decreased, suggesting a potential shift towards more localized or specific clinical studies in developed regions.
  4. Basic Science Research in Animal Models:
    There is a decline in the publication of studies focusing on basic science research using animal models. This may indicate a trend towards translational research that connects laboratory findings more directly with clinical applications.

Similar Journals

Neurodegenerative Diseases

Elevating research on the spectrum of neurodegeneration.
Publisher: KARGERISSN: 1660-2854Frequency: 4 issues/year

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.

Tumori Journal

Leading the Way in Cancer Understanding and Care.
Publisher: SAGE PUBLICATIONS LTDISSN: 0300-8916Frequency: 6 issues/year

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Clinical Obesity

Transforming Understanding into Action
Publisher: WILEYISSN: 1758-8103Frequency: 6 issues/year

Clinical Obesity, published by WILEY, is a leading journal in the field of Endocrinology, Diabetes, and Metabolism that strives to advance the understanding of obesity-related health issues. With an ISSN of 1758-8103 and an E-ISSN of 1758-8111, this journal provides a platform for cutting-edge research and findings pertaining to the epidemiology, pathophysiology, prevention, and treatment of obesity. Recognized with a Q2 ranking in both Endocrinology, Diabetes and Metabolism and Medicine (miscellaneous) categories, and boasting a Scopus rank of #90 out of 244, Clinical Obesity encompasses innovative studies that influence clinical practice and public health policies. While this journal operates under a subscription model, its discipline-specific contributions are invaluable for researchers, healthcare professionals, and students keen on addressing the complexities of obesity in a comprehensive manner.

ACTA NEUROLOGICA SCANDINAVICA

Pioneering Research in Neurology
Publisher: WILEYISSN: 0001-6314Frequency: 12 issues/year

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

Epilepsy & Behavior Reports

Driving Forward the Dialogue on Epilepsy and Behavior
Publisher: ELSEVIER SCIENCE INCISSN: Frequency: 1 issue/year

Epilepsy & Behavior Reports, a distinguished journal published by ELSEVIER SCIENCE INC, specializes in the latest research and developments in the field of epilepsy and related behavioral conditions. Since its inception in 2019 as a fully Open Access journal, it has carved a niche for itself within the scientific community, providing an essential platform for researchers and clinicians focused on behavioral neuroscience and neurology. The journal's commitment to disseminating high-quality research is reflected in its current rankings within Scopus, placing it within the Q3 category for Behavioral Neuroscience and Clinical Neurology, underscoring its relevance to emerging trends in these fields. Located in the heart of New York, the journal strives to foster collaboration and innovation, making it a vital resource for academics, practitioners, and students eager to advance their understanding of epilepsy and its behavioral implications. The convergence of expertise and research in Epilepsy & Behavior Reports promises to illuminate crucial aspects of neurological health, driving forward the discourse that shapes future treatment and understanding of epilepsy.

Oncology Research and Treatment

Empowering the future of oncology with cutting-edge insights.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

ACTA NEUROLOGICA BELGICA

Elevating Clinical Practice Through Rigorous Research.
Publisher: SPRINGER HEIDELBERGISSN: 0300-9009Frequency: 4 issues/year

ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.

NEUROLOGY

Connecting professionals with cutting-edge neurological findings.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0028-3878Frequency: 48 issues/year

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

Movement Disorders Clinical Practice

Championing advancements in neurology and clinical practice.
Publisher: WILEYISSN: 2330-1619Frequency: 8 issues/year

Movement Disorders Clinical Practice, published by WILEY, is an essential peer-reviewed journal dedicated to advancing the understanding and treatment of movement disorders from a clinical perspective. With an ISSN of 2330-1619, this journal serves as a vital resource for researchers, clinicians, and students engaged in neurology and clinical neuroscience. Since its inception in 2014, the journal has established itself within the medical community, currently positioned in the Q2 category for both Neurology and Neurology (Clinical), reflecting its influence and reputation. Although it does not offer open access, the journal is integral for disseminating high-quality research and clinical insights, thereby contributing significantly to improved patient care and outcomes in the field of movement disorders. Based in Hoboken, NJ, it continues to attract contributions from leading experts and aims to foster a deeper understanding and dialogue surrounding contemporary challenges and advancements in movement disorder treatment.

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Unlocking insights into seizure disorders.
Publisher: W B SAUNDERS CO LTDISSN: 1059-1311Frequency: 10 issues/year

SEIZURE - EUROPEAN JOURNAL OF EPILEPSY is a leading journal published by W B SAUNDERS CO LTD, specializing in the field of epilepsy and seizure disorders. Since its inception in 1992, this journal has committed itself to advancing research and understanding in neurology, achieving a respectable 2023 impact factor reflected by its Q2 rankings in Medicine (miscellaneous), Neurology, and Clinical Neurology categories. With an impressive Scopus ranking that places it in the top 35% of journals in Neuroscience and Neurology, SEIZURE is dedicated to promoting high-quality research and clinical studies that offer insights into epilepsy management and treatment. Although not an open-access journal, it maintains a diverse array of original articles, reviews, and case studies catering to academicians, medical professionals, and students looking to expand their knowledge on epilepsy. This journal is pivotal for those seeking to stay abreast of the latest trends, therapies, and findings in the neuroclinical landscape.